Compare AGX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | CRSP |
|---|---|---|
| Founded | 1961 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.8B |
| IPO Year | 1995 | 2016 |
| Metric | AGX | CRSP |
|---|---|---|
| Price | $259.74 | $48.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 23 |
| Target Price | ★ $570.50 | $74.33 |
| AVG Volume (30 Days) | 282.8K | ★ 1.4M |
| Earning Date | 09-02-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ 58.37 | N/A |
| EPS | ★ 7.01 | N/A |
| Revenue | ★ $944,606,000.00 | $289,590,000.00 |
| Revenue This Year | $48.32 | $1,091.30 |
| Revenue Next Year | $20.43 | $216.80 |
| P/E Ratio | $41.46 | ★ N/A |
| Revenue Growth | 8.06 | ★ 9169.85 |
| 52 Week Low | $276.28 | $44.12 |
| 52 Week High | $805.75 | $63.45 |
| Indicator | AGX | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 29.90 | 49.65 |
| Support Level | N/A | $50.02 |
| Resistance Level | $447.21 | $60.68 |
| Average True Range (ATR) | 19.01 | 2.33 |
| MACD | -1.11 | 0.21 |
| Stochastic Oscillator | 11.62 | 52.19 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Teledata, out of which Power Services derives the majority of revenue.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.